NCT06509126View on ClinicalTrials.gov

Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

June 12, 2024

Primary Completion Date

January 31, 2028

Study Completion Date

June 30, 2028

Conditions
Colorectal Cancer Stage IV
Interventions
DRUG

Panitumumab

Administered at the dosage of 6mg/kg as 60 minutes, or 90 minutes for doses over 1000 mg, intravenous infusion

DRUG

Irinotecan

Administered at the dosage of 180 mg/m2 over 60 minutes intravenous infusion

DRUG

5-fluorouracil

Administered at the dosage of 400 mg/m2 (bolus intravenous infusion) followed by continuous intravenous infusion over 46 hours at the dosage of 2400 mg/m2

DRUG

L-folinic acid

Administered at the dosage of 200 mg/m2 over 120 minutes as intravenous infusion

Trial Locations (1)

80131

RECRUITING

Istituto Nazionale Tumori di Napoli - IRCCS - Fondazione G. Pascale, Napoli

All Listed Sponsors
lead

National Cancer Institute, Naples

OTHER